2 penny stocks this Fool thinks could deliver phenomenal returns!

Penny stocks are a risky but exciting asset class to invest in, prone to wild volatility. Our writer thinks he’s found two with the potential for success.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Stack of British pound coins falling on list of share prices

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny stocks are not for everybody. Some find them too risky for their appetite, preferring well-established stocks they know and trust. Others enjoy the opportunity to grab a cheap bargain and make potentially life-changing gains. It all depends on an individual’s investment strategy.

With that in mind, here are two low-cap stocks that I think seem to be on the right trajectory.

Targeting sustainable energy

With a £51.1m market cap and share price of 1.3p, Helium One (LSE:HE1) is very much in penny stock territory. 

As the name suggests, it’s an energy prospecting company that explores and develops sites for helium gas extraction. It currently operates three projects in Tanzania, the largest of which, Rukwa, is developed and almost ready for extraction. The company has a strong focus on sustainability and carries out environmental and social impact assessment (ESIA) studies to help it secure appropriate licensing. 

However, it’s not profitable yet and has been burning through cash quickly. Reports suggest it has around $8.7m left but fortunately, it remains debt-free for now. Over the past year, the share price fell 80% but recently things have improved, with it gaining 30% since early April. 

So are things turning around?

Analysts at Liberum think so. They believe the company is on the verge of tapping “world-class” concentrations of helium at its Itumbula site in Rukwa. The London-based investment bank calculates the shares could be worth as much as 5.3p based on the commercial value of the untapped gas.

Naturally, investing in mining can be risky, particularly when the resource has only been discovered and extraction is yet to begin. Should Helium One succeed, it could spell huge profits for the company. But if its cash runs out before it becomes profitable it could spell disaster.

A niche medical company

With the share price now up to 103p, Diaceutics (LSE:DXRX) is technically a penny stock no more. But with a market value of only £87m, it’s still a very small-cap company. 

It appears to have a good business model of providing sought-after diagnostic testing for the precision medicine industry. Despite its small size, it reportedly works with 21 of the top 30 pharmaceutical companies in the world. As evident on the chart below, it was in high demand during the pandemic but has since struggled to enjoy the same success.

That’s notably the key risk the company faces. It’s in a very niche sector, reliant on sustained demand for specialist medical diagnosis. While it doesn’t appear to have any direct competitors currently, it could be priced out of the market by a leading pharma company. Profit margins are down to 0.03% from 0.8% last year and earnings growth lags behind share price growth –- suggesting lots of speculative buying. 

But despite limited growth in the past five years. the share price has done well recently, up 22% in six months. The company seems to be on the right track. Using a discounted cash flow model, analysts estimate the stock to be 78% undervalued. They’re also very bullish on it too, with the average 12-month price target at £1.67. That’s a 60% increase!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Nvidia share price dips despite strong Q3 results. What can we expect now?

Despite posting strong Q3 results after yesterday's market close, the Nvidia share price slipped 2.5% in aftermarket trading. Mark Hartley…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

An outstanding interim report sends the Halma share price surging 10%

News of 13% revenue growth and a 17% increase in earnings per share has the Halma share price rising. And…

Read more »

Investing Articles

With 2025 on the horizon, what’s the dividend forecast for Rolls-Royce shares?

As 2024 rolls to an end, our writer considers the forecast for Rolls-Royce shares after the company reinstated dividends earlier…

Read more »

Investing Articles

Where might the Rolls-Royce share price be in 12 months? Here’s what the experts say

The Rolls-Royce share price has more than doubled since November 2023. But analysts have a wide range of opinions as…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

As Shell’s share price continues to drift lower despite strong Q3 results, should I buy more?

Shell’s share price is down 14% from its one-year traded high, despite strong recent results, leaving the shares looking undervalued…

Read more »

Investing Articles

Here are 2 of my favourite cheap shares to buy today

Harvey Jones is on the hunt for cheap shares and was surprised to discover these two big-name FTSE 100 stocks…

Read more »

Investing Articles

Where could the BT share price go in the next 12 months? Check out the latest forecasts

The BT share price has had a bumpy ride but has nevertheless attracted the attention of two famous billionaire investors.…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This FTSE 250 share has surged 20% in a month. Its P/E is still just 3.3. So should I buy?

Our writer thinks this FTSE 250 stock remains enticing, with an ultra-low P/E ratio and an attractive yield. But why's…

Read more »